Molecular marker for osteoporosis and application of marker

A technology for osteoporosis and products, applied in the treatment, LYPD3 gene in the field of diagnosis of osteoporosis, can solve the problem of not being able to screen patients with osteoporosis

Active Publication Date: 2015-12-09
GUAN BOJIAN BIOTECH CO LTD
View PDF3 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The objects of auxiliary examination are generally patients with advanced ost...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker for osteoporosis and application of marker
  • Molecular marker for osteoporosis and application of marker
  • Molecular marker for osteoporosis and application of marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1 Differential expression of LYPD3 gene in blood

[0065] 1. Research objects:

[0066] Randomly select patients who are about to undergo marrow joint replacement surgery to detect bone density, select 50 patients with osteoporosis, and 40 patients with normal bone density control group (traumatic fracture, no osteoporosis detected), aged 50-70 years. Questionnaire surveys the subjects’ lifestyle and health status.

[0067] Inclusion criteria for patients with osteoporosis: (1) Those who meet the diagnostic criteria for osteoporosis, refer to the "Chinese Osteoporosis Recommended Diagnostic Criteria (Second Draft); (2) All patients have informed consent.

[0068] Exclusion criteria for patients with osteoporosis: those with secondary osteoporosis.

[0069] 2. Extraction of total RNA from blood

[0070] Use Biotech blood RNA extraction kit to extract total RNA from blood

[0071] (1) Take 250μl (or 0.25g) of whole blood into the RNase-Free filter column, centrifuge at 13000...

Embodiment 2

[0105] Example 2 Differential expression of LYPD3 gene in bone tissue

[0106] 1. Research objects:

[0107] Randomly select patients who are about to undergo marrow joint replacement surgery to detect bone density, select 50 patients with osteoporosis, and 40 patients with normal bone density control group (traumatic fracture, no osteoporosis detected), aged 50-70 years. Questionnaire surveys the subjects’ lifestyle and health status.

[0108] Inclusion criteria for patients with osteoporosis: (1) Those who meet the diagnostic criteria for osteoporosis, refer to the "Chinese Osteoporosis Recommended Diagnostic Criteria (Second Draft); (2) All patients have informed consent.

[0109] Exclusion criteria for patients with osteoporosis: those with secondary osteoporosis.

[0110] 2. Obtaining RNA from bone tissue

[0111] From the human femoral head removed from the marrow joint replacement, 1g of hard bone was taken and quickly stored in liquid nitrogen. Trizol is used in the laboratory ...

Embodiment 4

[0130] Example 4 Inhibition of LYPD3 gene expression

[0131] 1. Experiment grouping:

[0132] The experiment is divided into four groups: negative control group (siRNA-NC), siRNA1-LYPD3 group, siRNA2-LYPD3 group, siRNA3-LYPD3 group.

[0133] 2. siRNA design and synthesis

[0134] SiRNA was designed and synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd.

[0135] siRNA1-LYPD3:

[0136] The sense strand is 5'-AUUUAUGUGCCAGAAACUGAU-3' (SEQIDNO.7);

[0137] The antisense strand is 5'-CAGUUUCUGGCACAUAAAUGC-3' (SEQIDNO.8),

[0138] siRNA2-LYPD3:

[0139] The sense strand is 5'-AAUUAAAUCUUUAUUGAGGCA-3' (SEQIDNO.9);

[0140] The antisense strand is 5'-CCUCAAUAAAGAUUUAAUUAC-3' (SEQIDNO.10),

[0141] siRNA3-LYPD3:

[0142] The sense strand is 5'-AGUAAUUAAAUCUUUAUUGAG-3' (SEQIDNO.11);

[0143] The antisense strand is 5'-CAAUAAAGAUUUAAUUACUUU-3' (SEQIDNO.12),

[0144] Negative control siRNA sequence (siRNA-NC):

[0145] The sense strand is 5'-CGUACGCGGAAUACUUCGA-3' (SEQIDNO.13);

[0146] The ant...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an LYPD3 gene and an expression product thereof both of which can serve as molecular markers for diagnosing osteoporosis. According to the LYPD3 and the expression product disclosed by the invention, a QPCR (quantitative polymerase chain reaction) experiment and a Western blot experiment provide that the LYPD3 gene has expression difference in blood or bone tissues of a normal person and an osteoporosis patient and can be used as an index for early diagnosis of the osteoporosis. In addition, the invention also discloses the LYPD3 gene and the expression product thereof both of which can serve as targets for diagnosing the osteoporosis and be used for guiding the research and development of novel medicaments.

Description

Technical field [0001] The present invention relates to the field of biotechnology, in particular to the use of LYPD3 gene in the diagnosis and treatment of osteoporosis. Background technique [0002] Osteoporosis (osteoporosis) is a systemic bone disease characterized by decreased bone mass and destruction of the fine structure of bone, manifested by increased fragility of the bone, and thus the risk of fracture is greatly increased, even with minor trauma or Fractures are prone to occur without trauma. Vertebral compression fractures often occur unconsciously, and vertebral fractures can also be induced by coughing, sneezing, and minor trauma. Osteoporosis is a chronic disease caused by multiple factors. Before the fracture occurs, there is usually no special clinical manifestations. The disease is more common in women than men, but it can develop at all ages, and it is common in postmenopausal women and the elderly. With the increase in the elderly population in my country...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68G01N33/68A61K45/00A61K31/7088A61K39/395A61P19/10
CPCA61K31/7088A61K39/395A61K45/00C12Q1/6883C12Q2600/158G01N33/6893G01N2333/47G01N2800/108
Inventor 董东杨承刚
Owner GUAN BOJIAN BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap